Also, the combination with OX40 costimulation holds potential, supported by the observation that treatment with an agonistic OX40 antibody and a TGF-β receptor signaling inhibitor (SM16) led to tumor regression in diverse mouse models [43, 44]. This evidence concerns the gene TNFRSF4 and neoplasm.